These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

865 related articles for article (PubMed ID: 26514172)

  • 1. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
    Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
    J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Light-Induced Radiosynthesis of
    Klingler S; Fay R; Holland JP
    J Nucl Med; 2020 Jul; 61(7):1072-1078. PubMed ID: 31924725
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
    J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
    Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
    Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
    Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
    Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zirconium- 89 Labeled Antibody K1-70 for PET Imaging of Thyroid-stimulating Hormone Receptor Expression in Thyroid Cancer.
    Parent EE; Gleba JJ; Knight JA; Kenderian SJ; Copland JA; Cai H
    Mol Imaging Biol; 2024 Oct; 26(5):847-857. PubMed ID: 39174789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
    Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models.
    Kang L; Jiang D; Ehlerding EB; Barnhart TE; Ni D; Engle JW; Wang R; Huang P; Xu X; Cai W
    Mol Pharm; 2018 Apr; 15(4):1627-1634. PubMed ID: 29537283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Specifically Labeled
    Zheng M; Liu Q; Zhang H; Wang Y; Zhang K; Mu H; Fu F; Zhang X; Wang Y; Miao L
    Mol Pharm; 2024 Oct; 21(10):5205-5216. PubMed ID: 39322604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
    Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
    Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
    Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS
    J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total-Body PET and Highly Stable Chelators Together Enable Meaningful
    Berg E; Gill H; Marik J; Ogasawara A; Williams S; van Dongen G; Vugts D; Cherry SR; Tarantal AF
    J Nucl Med; 2020 Mar; 61(3):453-460. PubMed ID: 31562219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4
    Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
    Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Pandya DN; Bhatt NB; Almaguel F; Rideout-Danner S; Gage HD; Solingapuram Sai KK; Wadas TJ
    J Nucl Med; 2019 May; 60(5):696-701. PubMed ID: 30442753
    [No Abstract]   [Full Text] [Related]  

  • 17. Advancing
    Wuensche TE; Stergiou N; Mes I; Verlaan M; Schreurs M; Kooijman EJM; Janssen B; Windhorst AD; Jensen A; Asuni AA; Bang-Andersen B; Beaino W; Dongen GAMS; Vugts DJ
    Theranostics; 2022; 12(16):7067-7079. PubMed ID: 36276653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.
    Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS
    J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Development of CD38-Targeted [
    Ghai A; Maji D; Cho N; Chanswangphuwana C; Rettig M; Shen D; DiPersio J; Akers W; Dehdashti F; Achilefu S; Vij R; Shokeen M
    J Nucl Med; 2018 Feb; 59(2):216-222. PubMed ID: 29025987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A radiopharmaceutical [
    Tang Y; Hu Y; Liu W; Chen L; Zhao Y; Ma H; Yang J; Yang Y; Liao J; Cai J; Chen Y; Liu N
    Nucl Med Biol; 2019 Mar; 70():23-31. PubMed ID: 30826708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.